Jan 21, 2025, 15:29
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared an article by Wan-Qin Chong on X:
“Randomized phase II study in The Lancet Oncology shows that adding bevacizumab to pembrolizumab in previously treated nasopharygeal carcinoma improves RR (58.3% vs 12.5%) and significantly increased PFS to 13.8m from 1.6m: HR 0.25!”
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Authors: Wan-Qin Chong, et al.
More posts featuring Stephen V Liu.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29